Cancer and COVID-19: A Double Burden on the Healthcare System

doi:10.32592/ircmj.2023.25.2.2662

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of various malignant tumors has been steadily increasing, making cancer the leading cause of death in recent years 1,2 . In this regard, immunotherapy has played an important role in cancer treatment, standing as the fourth treatment pathway following surgery, chemotherapy, and radiotherapy as the fourth major treatment pathway 3 .…”

Section: Introductionmentioning

confidence: 99%

The Power of Nanovaccines in Immunotherapy of Melanoma, Lung, Breast, and Colon Cancers: A Comprehensive Review

Angaji,

Salim,

Azizi

et al. 2023

Res. Biotechnol. Environ. Sci.

View full text Add to dashboard Cite

Scientists are exploring new approaches to overcome cancer, and nanovaccines have emerged as one of the most promising tools in the fight against cancer. This review aimed to provide a thorough overview of nanovaccines as potential cancer immunotherapy agents by describing their mechanism of action and potential therapeutic implications. The growing incidence of cancer underscores the urgent need for comprehensive strategies focusing on prevention, early detection, and innovative treatment modalities to control and mitigate the impact of this widespread disease effectively. It is important to note that nanovaccines are a cutting-edge platform with a wide range of applications in immunotherapy for colon, breast, lung, melanoma, and ovarian cancers. Nanoscale formulations of tumor-specific antigens and adjuvants can initiate an efficient and targeted immune response. Research on nanovaccines involving melanoma has shown that they can trigger potent anti-tumor immune responses, which permit prolonged survival and tumor regression. Furthermore, nanovaccines have been effective in treating breast cancer since they can modulate the tumor microenvironment and stimulate the presence of cytotoxic T cells within the tumor. The nanovaccines strategy has enhanced the immune system’s recognition of tumor antigens, resulting in tumor cell destruction and effective immune recognition. There have also been studies that have utilized nanovaccines to modify the immune response of tumor cells to immune checkpoint inhibitors, thereby improving the synergistic outcomes of colon cancer treatment. Besides improving the immune response to malignancies, nanovaccines represent a transformative approach to cancer immunotherapy. The presence of compelling results across various cancer types suggests that nanovaccines are a powerful tool in cancer treatment despite further research required to optimize their design and validate their clinical applicability.

show abstract

Section: Introductionmentioning

confidence: 99%

The Power of Nanovaccines in Immunotherapy of Melanoma, Lung, Breast, and Colon Cancers: A Comprehensive Review

Angaji,

Salim,

Azizi

et al. 2023

Res. Biotechnol. Environ. Sci.

View full text Add to dashboard Cite

show abstract

The use of curcumin in the treatment of colorectal, breast, lung, and prostate cancers: An in vivo study update

Dolatkhah Laein,

Safarian,

Delasaeimarvi

et al. 2023

J Lab Anim. Res

View full text Add to dashboard Cite

Introduction: Cancer is one of the most prevalent and complex diseases with diverse etiology and manifestations. Curcumin is a bioactive compound found in turmeric and could have therapeutic potential for cancer due to its antitumor properties. Curcumin's properties in treating various types of cancer have been reviewed in this systematic review based on in vivo studies. Materials and methods: This systematic review focused on in vivo studies examining Curcumin's anti-cancer properties across a broad range of cancer types. PubMed, Google Scholar, and Scopus databases were searched to identify relevant articles. Researchers selected studies evaluating Curcumin's effects on cancer progression and development based on animal models. Final analyses were conducted on the data obtained from the selected articles. The included studies were published between 2000 and 2023. Results: The current systematic review was based on 53 articles out of 412 eligible studies, which were selected from 770 articles of literature screened from 2000 to 2023. Based on this review, in vivo studies have demonstrated that curcumin can potentially treat various cancers. There is evidence that curcumin has significant anti-cancer properties, including tumor growth inhibition, metastasis inhibitory activity, and angiogenesis. Several studies have demonstrated the versatility and potential of curcumin in treating cancer. Conclusion: Curcumin has considerable cancer treatment potential, based on the in-vivo studies. For curcumin to be considered an effective cancer therapy, further clinical research is needed between preclinical and clinical trials.

show abstract

Cancer and COVID-19: A Double Burden on the Healthcare System

Cited by 2 publications

References 51 publications

The Power of Nanovaccines in Immunotherapy of Melanoma, Lung, Breast, and Colon Cancers: A Comprehensive Review

The Power of Nanovaccines in Immunotherapy of Melanoma, Lung, Breast, and Colon Cancers: A Comprehensive Review

The use of curcumin in the treatment of colorectal, breast, lung, and prostate cancers: An in vivo study update

Contact Info

Product

Resources

About